Manufacturing process for memantine
US-9452971-B2 · Sep 27, 2016 · US
Compounds and methods for treating or preventing disease conditions associated with α-1-antitrypsin
US8993525B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8993525-B2 |
| Application number | US-201113879160-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 14, 2011 |
| Priority date | Oct 14, 2010 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Pharmacological chaperone compounds and methods for the treatment of an individual having, or at risk of having, a disease condition associated with alpha-1-antitrypsin by using said compounds are disclosed. In particular, such methods are useful for the treatment or prevention of lung disorders associated with alpha-1-antitrypsin deficiency as well as liver disorders associated with an excess of alpha-1-antitrypsin. Suitable pharmacological chaperones include peptides and low-molecular weight compounds. Also provided is an assay for determining whether a test compound modulates alpha-1-antitrypsin activity.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound according to the structure: wherein: R1 is —(CH 2 ) 2 —COOH or —CH 2 —OH R2 is —CH 3 or —CH—(CH 3 ) 2 . 2. The compound of claim 1 , wherein R1 is —CH 2 —OH and R2 is —CH 3 . 3. The compound of claim 1 , wherein R1 is —(CH 2 ) 2 —COOH and R2 is —CH—(CH 3 ) 2 . 4. Th…
Assignees
Inventors
Classifications
- C07C231/06Primary
Chemistry & Metallurgy · mapped topic
- A61K38/07Primary
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Physics · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8993525B2 cover?
- Pharmacological chaperone compounds and methods for the treatment of an individual having, or at risk of having, a disease condition associated with alpha-1-antitrypsin by using said compounds are disclosed. In particular, such methods are useful for the treatment or prevention of lung disorders associated with alpha-1-antitrypsin deficiency as well as liver disorders associated with an excess …
- Who is the assignee on this patent?
- Sjoberg Eric Richard, Lee Gary, Amicus Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07C231/06. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).